Donanemab

Donanemab (USAN; development code LY3002813) is a biological drug in trial to slow the progression of early Alzheimer's disease. There is currently no cure or disease-modifying treatment for Alzheimer's disease. Donanemab has shown positive results in Eli Lilly and Co.’s first three trials. Donanemab was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer’s disease. Donanemab, also known as N₃pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (Aβ). Whilst the cause of Alzheimer’s disease is still unknown, advances in amyloid pathology have discovered a likely relationship between the quantity of Aβ peptides and the development of Alzheimer's disease. Aβ peptides are deposited in the brain and when in excess will bind together to create a protein plaque. Donanemab targets this protein plaque, clearing the excess protein which causes a burden in the brain.